Germany’s leading venture capital firm High-Tech Gründerfonds and Russian Venture Capital – funded Maxwell Biotech Venture Fund have invested in Hepatera, a Russian startup that develops drugs for the prevention and treatment of liver diseases, and its German partner company MYR GmbH. The new investment will be used for clinical trial program.
Founded in September 2011, Hepatera (Гепатера) develops Myrcludex B, a drug that is aimed at the treatment of chronic viral hepatitis B and D. Hepatera develops the drug in close partnership with MYR. Last December, Hepatera became a resident of the Biomedical Cluster at Skolkovo Innovation Center.
Founded by Dr. Alexander Alexandrov in 2010, MYR holds the worldwide exclusive product rights for Myrcludex B. Based near Hannover, MYR is focused on the coordination of a network of academic partners and vendors involved in Myrcludex’s development. In May 2011, High-Tech Gründerfonds invested EUR 0.5 million in MYR for Phase 1 of its clinical testing at the University Clinic Heidelberg after completion of its pre-clinical studies.
Launched in late 2008, Maxwell Biotech Venture Fund, which has $100 million capital under management, has invested in OncoMax (oncology), NeuroMax (CNS), MetaMax (oncology and metabolic diseases), Infectex (infectious diseases), CardioNova (cardiovascular diseases), Hepatera (liver diseases) and Photonics (novel lasers for medicine and dentistry).